Efficacy of platelet transfusions during standard induction chemotherapy in patients with acute myeloid leukemia

Davaasambuu1, S.V. Gritsayev2, T.V. Glazanova2, S.A. Tiranova2, N.A. Potikhonova2, I.S. Martynkevtch2, and A.V. Chechetkin2

1 I.I. Mechnikov Northwest State Medical University, RF Ministry of Health, Saint Petersburg, Russian Federation

2 Russian Research Institute of Hematology and Transfusiology, RF FMBA, Saint Petersburg, Russian Federation


ABSTRACT

The efficacy of platelet transfusions that is mainly determined by the immunological mechanisms still depends on the non-immunological factors causing the low platelet count increment after transfusions. The objective of the study was to identify clinical and hematological parameters that were associated with the efficacy of the platelet transfusions during induction chemotherapy according to “7+3” regimen in the patients with acute myeloid leukemias (AML) The data on 41 patients (median age: 42) were analyzed. The platelet transfusion was considered efficacious when the 24-corrected platelet count increment was ³ 4.5 ´ 109/L. The patients were divided into 2 groups according to the efficacy ³ 50 % or < 50 %, respectively. The groups showed no significant difference with respect to the age, AML variants according to the WHO classification and ELN prognostic scale, the response to chemotherapy, or the median of overall survival (OS). At the same time, the portion of the patients with the bone marrow (BM) blasts of myeloid origin (M1 and M2 variants of AML according to FAB classification) was greater in the group with the platelet transfusion efficacy of ³ 50 %. In the group of < 50 % platelet transfusion efficacy, there was the greater portion of patients with BM blasts of monocytic origin (M4 and M5 variants according to FAB classification (=.001). Also, the trend towards the decreased median of OS was noted in the patients with the pre-transfusion platelet count below 10 ´ 109/L (=0.049).


Keywords: acute myeloid leukemia, “7+3” induction chemotherapy, platelet transfusion.

Read in PDF (RUS)pdficon


REFERENCES

  1. Волкова М.А. (ред.) Клиническая онкогематология. М.: Медицина, 2007. [Volkova M.A. (red.) Klinicheskaya onkogematologiya (Volkova M.A. (ed.). Clinical oncohematology). M.: Meditsina, 2007.]
  2. Pulte D., Gondos A., Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica 2008; 93(4): 594–600.
  3. Derolf A.R., Kristinsson S.Y., Andersson T.M. et al. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed I Sweden between 1973 and 2005. Blood 2009; 113(16): 3666–73.
  4. Schiffer C.A., Anderson K.A., Bennett C.L. et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 2001; 19(5): 1519–38.
  5. Lim Y.A., Lee W.G., Cho S.R. et al. A study of blood usage by diagnoses in a Korean university hospital. Vox. Sang. 2004; 86(1): 54–61.
  6. Wells A.W., Llewelyn C.A., Casbard A. et al. The EASTR study: indications for transfusion and estimates of transfusion recipient numbers in hospitals supplied by the National Blood Service. Transfus. Med. 2009; 19(6): 315–28.
  7. Wandt H., Schaefer-Eckart K., Wendelin K. et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012; 380(9850): 1309–16.
  8. Stanworth S.J., Estcourt L.J., Powter G. et al. A no-prophylaxis platelettransfusion strategy for hematologic cancers. N. Engl. J. Med. 2013; 368(19): 1771–80.
  9. Hod E., Schwartz J. Platelet transfusion refractoriness. Br. J. Haematol. 2008; 142(3): 348–60.
  10. Slichter S.J., Davis K., Enright H. et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105(10): 4106–14.
  11. Leal-Noval S.R., Arellano-Orden V., Maestre-Romero A. et al. Impact of national transfusion indicators on appropriate blood usage in critically ill patients. Transfusion 2011; 51(9): 1957–65.
  12. Cognasse F., Payrat J.M., Corash L., Osselaer J.C., Garraud O. Platelet components associated with acute transfusion reactions: the role of platelet derived soluble CD40 ligand. Blood 2008; 112(12): 4779–80.
  13. Semple J.W., Italiano J.E. Jr., Freedman J. Platelets and the immune continuum. Nat. Rev. Immunol. 2011; 11(4): 264–74.
  14. Murphy M.F., Metcalfe P., Ord J., Lister T.A., Waters A.H. Disappearance of HLA and platelet-specific antibodies in acute leukaemia patients alloimmunized by multiple transfusions. Br. J. Haematol. 1987; 67(3): 255–60.
  15. Ishida A., Handa M., Wakui M. et al. Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation — a prospective analysis. Transfusion 1998; 38(9): 839–47.
  16. Li G., Liu F., Mao X., Hu L. The investigation of platelet transfusion refractory in 69 malignant patients undergoing hematopoietic stem cell transplantation. Transfus. Apher. Sci. 2011; 45(1): 21–4.
  17. Slichter S.J., Bolgiano D., Kao K.J. et al. Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products. Transfus. Med. Rev. 2011; 25(2): 102–10.
  18. Sintnicolaas K., van Marwijk Kooij M., van Prooijen H.C. et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood 1995; 85(3): 82482–8.
  19. Seftel M.D., Growe G.H., Petraszko T. et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004; 103(1): 333–9.
  20. Brand A., Claas F.H., Voogt P.J., Wasser M.N., Eernisse J.G. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions. Vox. Sang. 1988; 54(3): 160–6.
  21. Murphy M.F., Waters A.H. Platelet transfusions: The problem of refractoriness. Blood Rev. 1990; 4(1): 16–24.
  22. Jackman R.P., Deng X., Bolgiano D. et al. Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants. Blood 2013; 121(16): 3261–6.
  23. Doughty H.A., Murphy M.F., Metcalfe P. et al. Relative importance of immune and non-immune causes of platelet refractoriness. Vox. Sang. 1994; 66(3): 200–5.
  24. Vardiman J.W., Thiele J., Arber D.A. et al. The 2008 revision of the World Health Organisation (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2008; 114(5): 937–51.
  25. Bennett J.M., Catovsky D., Daniel M.T. et al. Proposals for the classification of the acute leukaemias. French–American–British (FAB) Cooperative Group. Br. J. Haematol. 1976; 33(4): 451–8.
  26. Dohner H., Estey E.H., Amadori S. et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115(3): 453–74.
  27. Cheson B.D., Bennett J.M., Kopecky K.J. et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J. Clin. Oncol. 2003; 21(24): 4642–9.
  28. Lowenberg B., Ossenkoppele G.J., van Putten W. et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N. Engl. J. Med. 2009; 361(13): 1235–48.
  29. Juliusson G. Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish acute leukemia registry. Clin. Lymph. Myeloma Leuk. 2011; 11(Suppl. 1): S54–9.
  30. Arellano M., Winton E., Pan L. et al. High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years. Cancer 2012; 118(2): 428–33.
  31. Грицаев С.В., Мартынкевич И.С., Мартыненко Л.С. и др. Возраст и кариотип — факторы риска у больных первичным острым миелоидным лейкозом. Клин. онкогематол. 2010; 3(4): 359–64. [Gritsayev S.V., Martynkevich I.S., Martynenko L.S., et al. Age and karyotype — risk factors in patients with primary acute myeloid leukemia. Klin. onkogematol. 2010; 3(4): 359–64. (In Russ.)].
  32. Бондаренко С.Н., Семенова Е.В., Вавилов В.Н. и др. Аллогенная трансплантация гемопоэтических стволовых клеток при остром миело- бластном лейкозе в первой ремиссии. Тер. арх. 2013; 7: 18–25. [Bondarenko S.N., Semenova Ye.V., Vavilov V.N., et al. Allogeneic hematopoietic stem cell transplantation in acute myelogeneous leukemia in first remission. Ter. arkh. 2013; 7: 18–25. (In Russ.)].
  33. Burnett A.K., Milligan D., Prentice A.G. et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007; 109(6): 1114–24.
  34. Грицаев С.В., Мартынкевич И.С., Кострома И.И. Азацитидин и миело- диспластический синдром. Гематол. и трансфузиол. 2012; 1: 23–9. [Gritsayev S.V., Martynkevich I.S., Kostroma I.I. Azacitidine and myelodisplastic syndrome. Gematol. i transfuziol. 2012; 1: 23–9. (In Russ.)].
  35. Zumberg M.S., Del Rosario M.L., Nejame C.F. et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients. Biol. Blood Marrow Transplant. 2002; 8(10): 569–76.
  36. Levin M.D., de Veld J.C., van der Holt B., van’t Veer M.B. Immune and nonimmune causes of low recovery from leukodepleted platelet transfusions: a prospective study. Ann. Hematol. 2003; 82(6): 357–62.
  37. Murphy M.F., Waters A.H. Immunological aspects of platelet transfusions. Br. J. Haematol. 1985; 60(3): 409–14.
  38. Oksanen K. Leukocyte-depleted blood components prevent platelet refractoriness in patients with acute myeloid leukemia. Eur. J. Haematol. 1994; 53(2): 100–7.
  39. Klumpp T.R., Herman J.H., Innis S. et al. Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation. Bone Marrow Transplant. 1996; 17(6): 1035–41.
  40. Balduini C.L., Salvaneschi L., Klersy C. et al. Factors influencing posttransfusional platelet increment in pediatric patients given hematopoietic stem cell transplantation. Leukemia 2001; 15(12): 1885–91.
  41. Saito S., Ota S., Seshimo H. et al. Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens. Transfusion 2002; 42(3): 302–8.
  42. Gordon B., Tarantolo S., Ruby E. et al. Increased platelet transfusion requirement is associated with multiple organ dysfunctions in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 1998; 22(10): 999–1003.
  43. Hall P.D., Benko H., Hogan K.R., Stuart R.K. The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp. Hematol. 1995; 23(12): 1256–60.
  44. Eljaafari A., van Snick J., Voisin A. et al. Alloreaction increases or restores CD40, CD54, and/or HLA molecule expression in acute myelogenous leukemia blasts, through secretion of inflammatory cytokines: dominant role for TNFbeta, in concert with IFNgamma. Leukemia 2006; 20(11): 1992–2001.
  45. Cimino G., Amadori S., Cava M.C. et al. Serum interleukin-2 (IL-2), soluble IL-2 receptors and tumor necrosis factor-alfa levels are significantly increased in acute myeloid leukemia patients. Leukemia 1991; 5(1): 32–5.
  46. Tsimberidou A.M., Estey E., Wen S. et al. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008; 113(7): 1605–13.
  47. Guarini A., Sanavio F., Novarino A. et al. Thrombocytopenia in acute leukaemia patients treated with IL2: cytolytic effect of LAK cells on megakaryocytic progenitors. Br. J. Haematol. 1991; 79(3): 451–6.
  48. Sekeres M.A., Elson P., Kalaycio M.E. et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood 2009; 113(1): 28–36.
  49. Bertoli S., Berard E., Huguet F. et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood 2013; 121(14): 2618–26.
  50. Kurzrock R., Kantarjian H., Wetzler M. et al. Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. Exp. Hematol. 1993; 21(1): 80–5.